---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-007497"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T16:49:22.736663+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx Q1 net loss $40.0M; announces $200M Hologen AI collaboration, RMAT for AAV-GAD

## Summary
- Q1 net loss $40.0M ($0.51/share) vs $20.4M ($0.32) YoY; revenue $1.9M; cash $66.5M.
- Hologen AI collaboration: $200M upfront to MeiraGTx; joint venture with $230M committed capital.
- FDA granted RMAT designation for AAV-GAD Parkinson's; Phase 3 study planned H2 2025.
- AAV-AIPL1 data in Lancet: 11/11 children with LCA4 responded; expedited approval discussions underway.
- Bota-vec Phase 3 XLRP trial primary endpoint not met; secondary endpoints showed benefit across vision domains.

## SEC filing metadata
- accession: 0001558370-25-007497
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000155837025007497/0001558370-25-007497-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000155837025007497/mgtx-20250513x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-007497
- JSON: https://secwatch.observer/filing/0001558370-25-007497.json
- Plain text: https://secwatch.observer/filing/0001558370-25-007497.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.